EDMUND K WALLER, M.D.
Osteopathic Medicine at Clifton Rd, Atlanta, GA

5800539, Sep 1, 1998

Nov 8, 1995

8/555520

Edmund K. Waller - Atlanta GA

Emory University - Atlanta GA

A61F 202, A61K 3512, A61K 3500, A61K 4900

623 11

The present invention provides a method of transplanting hematopoietic system reconstituting cells from a donor into an allogeneic recipient comprising administering to the recipient, prior to the administration of the hematopoietic system reconstituting cells, an amount of mononuclear cells which are treated so as to render them incapable of proliferating and causing a lethal graft versus host disease effect, but which are effective in enhancing subsequent engraftment of the hematopoietic system reconstituting cells in the recipient; and administering to the recipient an effective amount of hematopoietic system reconstituting cells.

6213127, Apr 10, 2001

Sep 3, 1998

9/068472

Edmund K. Waller - Atlanta GA

Emory University - Atlanta GA

A61B 1900

128898

The present invention provides a method of transplanting hematopoietic system reconstituting cells from a donor into an allogeneic recipient comprising administering to the recipient, prior to the administration of the hematopoietic system reconstituting cells, an amount of mononuclear cells which are treated so as to render them incapable of proliferating and causing a lethal graft versus host disease effect, but which are effective in enhancing subsequent engraftment of the hematopoietic system reconstituting cells in the recipient; and administering to the recipient an effective amount of hematopoietic system reconstituting cells.

6060643, May 9, 2000

Aug 4, 1995

8/511396

William H. Fleming - Atlanta GA
Edmund K. Waller - Atlanta GA
Curtis W. Turner - Marietta GA

Emory University - Atlanta GA

C12N 1500, A61K 3500

800 8

The present invention provides a non-human genetically immunodeficient mammal the peripheral blood of which contains a non-lethal percent of T-cells of human origin which is at least 20% as well as a non-human genetically immunodeficient mammal having a lethal percent of T-cells of human origin in the peripheral blood which is at least 60%. Also provided is a method of screening a substance for anti-HIV activity comprising obtaining a non-human genetically immunodeficient mammal having a lethal percent of human T-cells in the peripheral blood which is at least 60%; infecting the mammal with an amount of HIV sufficient to rescue the mammal from death from the effects of the lethal percent of human T-cells; administering the substance to the mammal; and determining if the substance kills the mammal by inhibiting the rescue of the mammal by HIV, the death of the mammal indicating a substance having anti-HIV activity.

6517830, Feb 11, 2003

Aug 4, 2000

09/633020

John S. Lollar - Decatur GA
Hung V. Do - Atlanta GA
John F. Healey - Snellville GA
Edmund K. Waller - Atlanta GA

Emory University - Atlanta GA

A01N 6300

424 9321, 514 44, 4353201

Compositions and methods are provided for the in vivo gene delivery of nucleic acid sequences encoding the factor VIII protein to the liver endothelial sinusoidal cells (LSECs). Compositions and methods are also provided for the ex vivo gene transfer of nucleic acid sequences encoding the factor VIII protein to cultured LSECs and the implantation of the transformed LSECs in vivo. These methods and compositions increase the level of factor VIII in the blood stream and find use in the gene therapy treatment of hemophilia A.

2005001, Jan 20, 2005

May 8, 2002

10/477012

Edmund Waller - Atlanta GA, US
Hilary Rosenthal - Lilburn GA, US
Sagar Lonial - Atlanta GA, US

A61K039/395

424144100, 424093710

Disclosed within a method of altering immune responses using dendritic cells. One form of the method is a method of inducing immunological tolerance in an individual, where type 2 dendritic cells are administrated to an individual, and where the dendritic cells have been incubated with one or more antigens. Another form of the method involves altering an immune response, in which liposomes containing where liposomes containing one or more antigens are administrated to an individual, and where the liposomes are modified with surface-bound molecules that target the liposomes to type 2 dendritic cells. Another form of the method involves reducing immune responsiveness, where liposomes containing one or more antigens are administrated to an individual and where the liposomes are modified with the surface bound molecules that target the liposomes to type 1 dendritic cells or type 2 dendritic cells. Another form of the method is a method of enhancing immune responsiveness, where liposomes containing one or more antigens are administrated to an individual, and where the liposomes are modified with surface-bound molecules that target the liposomes to mature type 1 dendritic cells.

8486408, Jul 16, 2013

Oct 2, 2009

13/121016

Mohammad S. Hossain - Norcross GA, US
Andrew T. Gewitz - Smyrna GA, US
John D. Roback - Smyrna GA, US
Edmund K. Waller - Atlanta GA, US

Emory University - Atlanta GA

A61K 35/28, A61K 39/085

4241721, 4242341, 4242581

Methods are disclosed for treating or preventing graft versus host disease in a subject. The methods include selecting a subject in need of treatment for graft versus host disease; and administering to the subject a therapeutically effective amount of a TLR5 agonist such as a flagellin polypeptide, or a polynucleotide encoding the flagellin, thereby treating or preventing graft versus host disease in the subject. Methods are also disclosed for reducing susceptibility to an opportunistic infection in a subject who is a bone marrow transplant recipient. The methods include selecting a subject who has had a bone marrow or hematopoietic stem cell transplant; and administering to the subject a therapeutically effective amount of a TLR5 agonist such as a flagellin polypeptide or a polynucleotide encoding the polypeptide, and administering to the subject an effective amount antigen of the opportunistic infection, thereby reducing the susceptibility to the opportunistic infection in the subject.

2003000, Jan 9, 2003

Jan 25, 2002

10/057288

Christian Larsen - Atlanta GA, US
Thomas Pearson - Atlanta GA, US
Edmund Waller - Atlanta GA, US
Andrew Adams - Atlanta GA, US

A61K039/395, A61K031/255, A61K045/00

424/144100, 424/093700, 514/517000

Methods of establishing hematopoietic chimerism useful to correct hematological diseases and promote acceptance of organ transplants include administering busulfan, costimulation blockade, and readily attainable numbers of T-cell depleted bone marrow cells.

2003012, Jul 10, 2003

Dec 3, 2002

10/308637

John Lollar - Decatur GA, US
Hung Do - Atlanta GA, US
John Healey - Snellville GA, US
Edmund Waller - Atlanta GA, US

Emory University

A61K048/00, C12N005/08, C12N015/867, C12N015/861

424/093210, 435/456000, 435/366000

Compositions and methods are provided for the in vivo gene delivery of nucleic acid sequences encoding the factor VIII protein to the liver endothelial sinusoidal cells (LSECs). Compositions and methods are also provided for the ex vivo gene transfer of nucleic acid sequences encoding the factor VIII protein to cultured LSECs and the implantation of the transformed LSECs in vivo. These methods and compositions increase the level of factor VIII in the blood stream and find use in the gene therapy treatment of hemophilia A.

2013030, Nov 14, 2013

Jan 31, 2012

13/979003

Edmund K. Waller - Atlanta GA, US
Jian-Ming Li - Altanta GA, US
Mohammad S. Hossain - Liburn GA, US

EMORY UNIVERSITY - Atlanta GA

A61K 39/395, A61K 38/16, A61K 38/04, A61K 39/245, A61K 35/14

4241591, 4242291, 424 937, 424 9371, 514 37, 514 42

The disclosure relates to inhibition of the VIP signaling pathway. In certain embodiments, the disclosure relates to methods of treating or preventing a viral infection comprising administering a VIP antagonist to a subject in need thereof.